澳大利亚和新西兰居家与中心透析的死亡率比较
该观察性研究比较了澳大利亚和新西兰1998-2017年透析起始队列中不同透析方式与死亡率的关联。在52,097例患者中,整体死亡率从1998-2002年的约15例/100患者年改善至2013-2017年的约11例/100患者年,感染性死亡下降贡献最大。2013-2017年,与中心血液透析相比,持续不卧床腹膜透析(CAPD)和自动化腹膜透析(APD)的调整风险比分别为0.88(95%CI 0.78-0.99)和0.91(95%CI 0.82-1.00);居家血液透析在整个观察期死亡率均较低。
要点
- 2013-2017年,CAPD和APD死亡率低于中心血液透析,调整HR分别为0.88和0.91。
- 居家血液透析在整个观察期死亡率均低于中心血液透析。
- 整体死亡率改善主要归因于感染性死亡减少。
核心结论
- 2013-2017年澳大利亚和新西兰腹膜透析患者的生存率似乎高于中心血液透析患者。
研究设计与样本
- 观察性研究,比较1998-2002、2003-2007、2008-2012和2013-2017四个透析起始队列,纳入澳大利亚和新西兰透析人群共52,097例患者。
主要发现
- 整体死亡率从1998-2002年的约15例/100患者年改善至2013-2017年的约11例/100患者年,感染性死亡下降贡献最大。
- 2013-2017年,与中心血液透析相比,CAPD的调整风险比为0.88(95%CI 0.78-0.99),APD为0.91(95%CI 0.82-1.00)。
- 居家血液透析在整个观察期死亡率均低于中心血液透析,尽管采用者中老年和合并症较多者增加。
- 效应对建模方法(初始vs时变方式、原因特异vs子分布回归)和随访时间(5年vs7年vs10年)普遍不敏感,且无糖尿病、合并症或性别的效应修饰。
临床怎么用
- 在澳大利亚和新西兰人群中,腹膜透析(尤其是CAPD和APD)及居家血液透析与中心血液透析相比可能带来生存获益,临床决策时可结合患者情况考虑居家透析方式。
局限性
- 存在残余混杂可能,结果外推性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Mortality is an important outcome for all dialysis stakeholders. We examined associations between dialysis modality and mortality in the modern era. STUDY DESIGN: Observational study comparing dialysis inception cohorts 1998-2002, 2003-2007, 2008-2012, and 2013-2017. SETTING & PARTICIPANTS: Australia and New Zealand (ANZ) dialysis population. EXPOSURE: The primary exposure was dialysis modality: facility hemodialysis (HD), continuous ambulatory peritoneal dialysis (CAPD), automated PD (APD), or home HD. OUTCOME: The main outcome was death. ANALYTICAL METHODS: Cause-specific proportional hazards models with shared frailty and subdistribution proportional hazards (Fine and Gray) models, adjusting for available confounding covariates. RESULTS: In 52,097 patients, the overall death rate improved from ~15 deaths per 100 patient-years in 1998-2002 to ~11 in 2013-2017, with the largest cause-specific contribution from decreased infectious death. Relative to facility HD, mortality with CAPD and APD has improved over the years, with adjusted hazard ratios in 2013-2017 of 0.88 (95% CI, 0.78-0.99) and 0.91 (95% CI, 0.82-1.00), respectively. Increasingly, patients with lower clinical risk have been adopting APD, and to a lesser extent CAPD. Relative to facility HD, mortality with home HD was lower throughout the entire period of observation, despite increasing adoption by older patients and those with more comorbidities. All effects were generally insensitive to the modeling approach (initial vs time-varying modality, cause-specific versus subdistribution regression), different follow-up time intervals (5 year vs 7 year vs 10 year). There was no effect modification by diabetes, comorbidity, or sex. LIMITATIONS: Potential for residual confounding, limited generalizability. CONCLUSIONS: The survival of patients on PD in 2013-2017 appears greater than the survival for patients on facility HD in ANZ. Additional research is needed to assess whether changing clinical risk profiles over time, varied dialysis prescription, and morbidity from dialysis access contribute to these findings.
引用
- Marshall MR, Polkinghorne KR, Boudville N, et al. Home Versus Facility Dialysis and Mortality in Australia and New Zealand. Am J Kidney Dis. 2021. PMID: 33992726. doi:10.1053/j.ajkd.2021.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。